Using Automated Nanoliter-Scale Immunoassays for Improved Performance and Efficiency
Therapeutic constructs such as bi-specifics, antibody drug conjugates and non-traditional therapeutics such as immunotherapies require more complex bioanalysis in measuring surrogate biomarker endpoints and pharmacokinetics (PK).
These complex analyses further complicate development. Automation and miniaturization using Gyrolab platforms redefine performance and efficiency in the development of these constructs, such as streamlined method development and reagent screening.
Gyrolab’s affinity flow-through format minimizes matrix effects to improve performance and eliminates incubations for more rapid time to results at a higher throughput. This webinar will present case studies featuring reagent screening and method development for a variety of different biotherapeutics – traditional and non-conventional constructs.
